Novavax stock: buy or sell?

NVAX stock price: $38.30 -5.83% At close on May 14th, 2020

Updated on:
May 14th, 2020


After climbing for 4 days, Thursday Novavax collapsed a hair-raising -5.83%, closing at $38.30. On May/12 NVAX skyrocketed an extraordinary 38.47%.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants.

Should I buy Novavax stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Novavax stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean NVAX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Novavax stock a buy?

Financial institutions and banks post stock ratings everyday. Unfortunately, we couldn't find any rating for NVAX stock for the last month.

Novavax stock analysis

Daily outlook

After climbing for 4 days, Thursday Novavax collapsed a hair-raising -5.83%, closing at $38.30.

After climbing for 4 days, Thursday Novavax collapsed a hair-raising -5.83%, closing at $38.30. Since SMA100d and SMA200d crossed up on March, NVAX price climbed $27.52 per share (255.29%). Since price and SMA200d lines crossed up on January, NVAX climbed $33.52 (701.26%).

NVAX stock chart (daily)

Weekly outlook

Novavax shares skyrocketed 104.48% this week, ending at $38.30. Late April NVAX plunged a frightening -14.43% in just one week.

Novavax shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom late April, NVAX stock climbed unceasignly breaking out above its last top at $26.34. Late February, SMA20w and SMA40w crossed up triggering a rise of 396.11%. Since price and SMA40w lines crossed up by mid January, NVAX climbed $34.37 (874.55%).

NVAX stock chart (weekly)

Novavax stock price history

Novavax stock went public on December 5th, 1995 with a price of $67.501. Since then, NVAX stock sliced a -43.30%, with a yearly average of -1.80%.

1: Adjusted price after possible price splits or reverse-splits.

Novavax stock historical price chart

NVAX stock reached 52-week highs on May 12th at $44.94, and all-time highs 2001-10-10 with a price of 311.

Novavax stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not found any price forecast for Novavax stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Novavax reported its latest financial data, posting a decent climb for the Earnings per Share (EPS) ratio. Analyst expected $-0.12 per share, but Novavax posted $-0.13.
NVAX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw a brilliant increase of 9.98% to $34.29 million dollars. Similarly, its profit margin (compared to sales) boosted to -538.81%, that is $-184.75 million.

NVAX annual Sales and Income evolution
2013$21 M-$-51.98 M-248.5%-
2014$31 M46.55%$-82.95 M-270.5%59.57%
2015$36 M18.24%$-156.94 M-432.9%89.20%
2016$15 M-57.65%$-279.97 M-1823.5%78.39%
2017$31 M103.06%$-183.77 M-589.5%-34.36%
2018$34 M9.98%$-184.75 M-538.8%0.53%

Quarterly financial results

Novavax reported $6.13 M in sales for 2018-Q4, a -20.79% less compared to previous quarter. Reported quarter income marked $-49.33 M with a profit margin of -805.19%. Profit margin plunged a -228.98% compared to previous quarter when profit margin was -576.21%. When comparing revenues to same quarter last year, Novavax sales marked a spooky slide and collapsed a -41.15%. Looking back to recent quarterly results, Novavax posted 2 positive quarters in a row.
NVAX quarterly Sales and Income evolution
2017-Q1$6 M-$-43.85 M-772.0%-
2017-Q2$7 M18.49%$-44.47 M-660.8%1.41%
2017-Q3$8 M24.10%$-44.61 M-534.1%0.31%
2017-Q4$10 M24.66%$-50.84 M-488.3%13.98%
2018-Q1$10 M-7.29%$-46.35 M-480.2%-8.83%
2018-Q2$11 M11.60%$-44.49 M-413.0%-4.01%
2018-Q3$8 M-28.20%$-44.57 M-576.2%0.18%
2018-Q4$6 M-20.79%$-49.33 M-805.2%10.69%

Novavax ownership

When you are planning to buy a stock, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novavax, 0.36% of all outstanding shares are owned by its staff.

In case of Novavax stock, 13.89% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVAX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Novavax:

Market cap$2.2 B
Total shares57.9 M
Float shares51.3 M
  - Institutional holdings (%)13.9%
  - Insider holdings (%)0.4%
Shares in short selling0.0%

Novavax summary

Thursday, May 14th, 2020
Day range$37.37 - $40.25
Previous close$40.67
Session gain-5.83%
Average true range$3.70
50d mov avg$16.93
100d mov avg$11.87
200d mov avg$8.43
Daily pattern
Weekly pattern lb03c

Novavax performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Novavax, the benchmark is made against .

Novavax competitors

Unfortunately, we could not find any public company that could be defined as Novavax competitor. This doesn't mean Novavax does not have any competitor in the market, it's just we could not detected it.